We are live on
!
Find out more
Jacobs Levy Equity Management Portfolio holdings
AUM
$23.8B
1-Year Est. Return
25.4%
This Fund
S&P 500
This Quarter
Est. Return
+3.06%
1 Year Est. Return
+25.4%
3 Year Est. Return
+87.35%
5 Year Est. Return
+125.75%
10 Year Est. Return
+515.94%
AUM
$4.68B
AUM Growth
-$270M
(-5.5%)
Cap. Flow
-$364M
Cap. Flow
% of AUM
-7.78%
Top 10 Holdings %
Top 10 Hldgs %
11.36%
Holding
1,103
New
193
Increased
369
Reduced
317
Closed
187
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Humana
HUM
|
+$25.2M |
| 2 |
Ashland
ASH
|
+$17.2M |
| 3 |
IBM
IBM
|
+$17.1M |
| 4 |
Madison Square Garden
MSGS
|
+$16.7M |
| 5 |
Valero Energy
VLO
|
+$16.1M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
CVS Health
CVS
|
+$35.9M |
| 2 |
Qualcomm
QCOM
|
+$29M |
| 3 |
BCR
CR Bard Inc.
BCR
|
+$27.5M |
| 4 |
Agilent Technologies
A
|
+$26.4M |
| 5 |
Northrop Grumman
NOC
|
+$25.1M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 19.21% |
| 2 | Financials | 19.14% |
| 3 | Healthcare | 11.97% |
| 4 | Industrials | 11.47% |
| 5 | Consumer Discretionary | 10.84% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
ECYT
826
DELISTED
Endocyte, Inc. Common Stock
ECYT
| $213K | ﹤0.01% |
141,772
+113,145
| +395% | +$243K |
|
|
827
Northrop Grumman
NOC
$75.8B
| $210K | ﹤0.01% |
819
-100,321
| -99% | -$25.1M |
|
828
Eversource Energy
ES
$28.1B
| $209K | ﹤0.01% |
3,450
| – | – |
|
829
Fossil Group
FOSL
$236M
| $209K | ﹤0.01% |
+20,200
| New | +$273K |
|
830
Civista Bancshares
CIVB
$588M
| $207K | ﹤0.01% |
+9,900
| New | +$208K |
|
|
SYNC
831
DELISTED
Synacor, Inc.
SYNC
| $207K | ﹤0.01% |
56,668
+25,800
| +84% | +$91.6K |
|
|
HDNG
832
DELISTED
Hardinge Inc
HDNG
| $207K | ﹤0.01% |
16,682
+6,400
| +62% | +$73.8K |
|
833
Universal Technical Institute
UTI
$2.13B
| $206K | ﹤0.01% |
57,600
+22,000
| +62% | +$79.3K |
|
|
ADVM
834
DELISTED
Adverum Biotechnologies
ADVM
| $205K | ﹤0.01% |
8,199
+5,754
| +235% | +$157K |
|
835
Citigroup
C
$221B
| $205K | ﹤0.01% |
3,070
-143,610
| -98% | -$8.81M |
|
|
MRLN
836
DELISTED
Marlin Business Services Corp
MRLN
| $205K | ﹤0.01% |
+8,170
| New | +$205K |
|
|
PRCP
837
DELISTED
Perceptron Inc
PRCP
| $205K | ﹤0.01% |
28,190
+10,400
| +58% | +$82.2K |
|
838
Aecom
ACM
$8.69B
| $204K | ﹤0.01% |
+6,310
| New | +$209K |
|
839
HubSpot
HUBS
$9.73B
| $204K | ﹤0.01% |
+3,100
| New | +$209K |
|
|
EGIO
840
DELISTED
Edgio, Inc. Common Stock
EGIO
| $202K | ﹤0.01% |
1,749
+80
| +5% | +$9.29K |
|
841
Barrett Business Services
BBSI
$977M
| $201K | ﹤0.01% |
14,000
-1,440
| -9% | -$20.5K |
|
|
PAMT
842
PAMT Corp
PAMT
$331M
| $201K | ﹤0.01% |
42,396
-7,200
| -15% | -$31.2K |
|
843
Aviat Networks
AVNW
$263M
| $200K | ﹤0.01% |
+23,014
| New | +$202K |
|
844
Eagle Bancorp
EGBN
$842M
| $200K | ﹤0.01% |
+3,160
| New | +$189K |
|
845
Vaalco Energy
EGY
$611M
| $197K | ﹤0.01% |
210,719
+148,221
| +237% | +$145K |
|
846
MannKind Corp
MNKD
$1.2B
| $197K | ﹤0.01% |
139,666
-57,580
| -29% | -$74.1K |
|
|
JNP
847
DELISTED
Juniper Pharmaceuticals, Inc. Common Stock
JNP
| $196K | ﹤0.01% |
38,901
+15,411
| +66% | +$68.9K |
|
|
PFNX
848
DELISTED
Pfenex Inc.
PFNX
| $194K | ﹤0.01% |
48,443
+8,000
| +20% | +$36.8K |
|
|
NAVB
849
DELISTED
Navidea Biopharmaceuticals Inc.
NAVB
| $193K | ﹤0.01% |
18,894
+12,144
| +180% | +$120K |
|
850
Larimar Therapeutics
LRMR
$417M
| $191K | ﹤0.01% |
4,532
+3,100
| +216% | +$159K |
|
Similar funds
OAG
CHP
SAM
JG
Jacobs Levy Equity Management's Q2 2017 Portfolio in Review
As of Q2 2017, Jacobs Levy Equity Management held 1,103 positions worth $4.68B, down 5.5% from $4.95B the previous quarter. Its ten largest holdings account for 11% of the portfolio.
Jacobs Levy Equity Management withdrew a net $364M in Q2 2017, closing 187 positions and reducing 317 holdings. Its most notable exit was CVS Health, an estimated $35.9M position sold in full.
By sector, the portfolio is most concentrated in Technology at 19% of assets, down from 20% a quarter earlier, followed by Financials and Healthcare.
Against the trend, Jacobs Levy Equity Management opened a new position in Humana worth $26.8M.
- Jacobs Levy Equity Management's largest Q2 2017 buy was Humana: 111,320 shares worth $26.8M.
- Jacobs Levy Equity Management added most to Madison Square Garden in Q2 2017, an estimated $16.7M increase.
- Jacobs Levy Equity Management's biggest Q2 2017 reduction was Agilent Technologies, cutting an estimated $26.4M.
- Jacobs Levy Equity Management fully exited CVS Health in Q2 2017, selling an estimated $35.9M.
- Jacobs Levy Equity Management's ten largest holdings make up 11% of its $4.68B portfolio in Q2 2017.
- Jacobs Levy Equity Management opened 193 new positions and closed 187 in Q2 2017.
- Jacobs Levy Equity Management's portfolio value fell 5.5% quarter-over-quarter to $4.68B.
Based on Jacobs Levy Equity Management's 13F filing for Q2 2017, filed 14 Aug 2017.